RU2016139700A - Pharmaceutical combination composition for the treatment of purulent wounds based on fluoroquinolones (options) - Google Patents
Pharmaceutical combination composition for the treatment of purulent wounds based on fluoroquinolones (options) Download PDFInfo
- Publication number
- RU2016139700A RU2016139700A RU2016139700A RU2016139700A RU2016139700A RU 2016139700 A RU2016139700 A RU 2016139700A RU 2016139700 A RU2016139700 A RU 2016139700A RU 2016139700 A RU2016139700 A RU 2016139700A RU 2016139700 A RU2016139700 A RU 2016139700A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- limited
- series
- substance selected
- antibiotic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 67
- 229940124307 fluoroquinolone Drugs 0.000 title claims 16
- 206010052428 Wound Diseases 0.000 title claims 4
- 208000027418 Wounds and injury Diseases 0.000 title claims 4
- 239000000126 substance Substances 0.000 claims 27
- 108090000790 Enzymes Proteins 0.000 claims 24
- 102000004190 Enzymes Human genes 0.000 claims 24
- 229940088598 enzyme Drugs 0.000 claims 24
- 239000003242 anti bacterial agent Substances 0.000 claims 18
- 230000003115 biocidal effect Effects 0.000 claims 16
- 239000002552 dosage form Substances 0.000 claims 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 9
- 230000001857 anti-mycotic effect Effects 0.000 claims 9
- 239000002543 antimycotic Substances 0.000 claims 9
- 239000002955 immunomodulating agent Substances 0.000 claims 9
- 229940121354 immunomodulator Drugs 0.000 claims 9
- 230000002584 immunomodulator Effects 0.000 claims 9
- 244000005700 microbiome Species 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 6
- 230000002421 anti-septic effect Effects 0.000 claims 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000000499 gel Substances 0.000 claims 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 5
- 229960001699 ofloxacin Drugs 0.000 claims 5
- 239000003306 quinoline derived antiinfective agent Substances 0.000 claims 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 3
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims 3
- DEWLFHSFHAHCCA-UHFFFAOYSA-J C(C(O)CO)(=O)[O-].[Si+4].C(C(O)CO)(=O)[O-].C(C(O)CO)(=O)[O-].C(C(O)CO)(=O)[O-] Chemical class C(C(O)CO)(=O)[O-].[Si+4].C(C(O)CO)(=O)[O-].C(C(O)CO)(=O)[O-].C(C(O)CO)(=O)[O-] DEWLFHSFHAHCCA-UHFFFAOYSA-J 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- 102000029816 Collagenase Human genes 0.000 claims 3
- 108060005980 Collagenase Proteins 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 229920002201 Oxidized cellulose Polymers 0.000 claims 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 3
- LRQIWRXCHWNNEA-MWZFJMJKSA-L [Cl-].[Cl-].CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C Chemical compound [Cl-].[Cl-].CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@@H]1C[C@H](C)CC[C@H]1C(C)C LRQIWRXCHWNNEA-MWZFJMJKSA-L 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 239000000443 aerosol Substances 0.000 claims 3
- 229940072056 alginate Drugs 0.000 claims 3
- 235000010443 alginic acid Nutrition 0.000 claims 3
- 229920000615 alginic acid Polymers 0.000 claims 3
- 229960004821 amikacin Drugs 0.000 claims 3
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 3
- UJRRDDHEMZLWFI-UHFFFAOYSA-N aminitrozole Chemical compound CC(=O)NC1=NC=C([N+]([O-])=O)S1 UJRRDDHEMZLWFI-UHFFFAOYSA-N 0.000 claims 3
- 229950000695 aminitrozole Drugs 0.000 claims 3
- 230000003444 anaesthetic effect Effects 0.000 claims 3
- 230000000844 anti-bacterial effect Effects 0.000 claims 3
- 108010044458 asperase Proteins 0.000 claims 3
- JQQZCIIDNVIQKO-UHFFFAOYSA-N benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC1=CC=CC=C1 JQQZCIIDNVIQKO-UHFFFAOYSA-N 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
- 229960003405 ciprofloxacin Drugs 0.000 claims 3
- 229960002424 collagenase Drugs 0.000 claims 3
- UOMKBIIXHQIERR-UHFFFAOYSA-N cridanimod Chemical compound C1=CC=C2N(CC(=O)O)C3=CC=CC=C3C(=O)C2=C1 UOMKBIIXHQIERR-UHFFFAOYSA-N 0.000 claims 3
- 229960003145 decamethoxine Drugs 0.000 claims 3
- 239000003599 detergent Substances 0.000 claims 3
- 239000003995 emulsifying agent Substances 0.000 claims 3
- 235000011187 glycerol Nutrition 0.000 claims 3
- 229960003376 levofloxacin Drugs 0.000 claims 3
- 229940040145 liniment Drugs 0.000 claims 3
- 239000000865 liniment Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000008297 liquid dosage form Substances 0.000 claims 3
- 108010013286 lysoamidase Proteins 0.000 claims 3
- 239000011777 magnesium Substances 0.000 claims 3
- 229910052749 magnesium Inorganic materials 0.000 claims 3
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 239000001923 methylcellulose Substances 0.000 claims 3
- 235000010981 methylcellulose Nutrition 0.000 claims 3
- 229960000282 metronidazole Drugs 0.000 claims 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 3
- 229960003702 moxifloxacin Drugs 0.000 claims 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 3
- 229960000808 netilmicin Drugs 0.000 claims 3
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 3
- 239000002674 ointment Substances 0.000 claims 3
- 229940107304 oxidized cellulose Drugs 0.000 claims 3
- 239000008055 phosphate buffer solution Substances 0.000 claims 3
- 229920005617 polyoxidonium Polymers 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 229940069328 povidone Drugs 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000008213 purified water Substances 0.000 claims 3
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 3
- -1 soft Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 239000007909 solid dosage form Substances 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 229960004954 sparfloxacin Drugs 0.000 claims 3
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 239000000829 suppository Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- MPMFCABZENCRHV-UHFFFAOYSA-N tilorone Chemical compound C1=C(OCCN(CC)CC)C=C2C(=O)C3=CC(OCCN(CC)CC)=CC=C3C2=C1 MPMFCABZENCRHV-UHFFFAOYSA-N 0.000 claims 3
- 229950006823 tilorone Drugs 0.000 claims 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 3
- 229960001082 trimethoprim Drugs 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 108010065073 lidase Proteins 0.000 claims 1
- 230000001937 non-anti-biotic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (51)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2016139700A RU2682171C2 (en) | 2016-10-11 | 2016-10-11 | Pharmaceutical combined composition for the treatment of purulent wounds on the basis of fluoroquinolons (options) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2016139700A RU2682171C2 (en) | 2016-10-11 | 2016-10-11 | Pharmaceutical combined composition for the treatment of purulent wounds on the basis of fluoroquinolons (options) |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016139700A true RU2016139700A (en) | 2018-04-11 |
RU2682171C2 RU2682171C2 (en) | 2019-03-15 |
Family
ID=61974614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016139700A RU2682171C2 (en) | 2016-10-11 | 2016-10-11 | Pharmaceutical combined composition for the treatment of purulent wounds on the basis of fluoroquinolons (options) |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2682171C2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2726982C1 (en) * | 2019-06-24 | 2020-07-17 | Акционерное Общество "Валента Фармацевтика" | Local application of dioxydine in infectious-inflammatory epithelial affection |
RU2770402C1 (en) * | 2021-03-15 | 2022-04-15 | Игорь Георгиевич Киселев | Composition for postoperative prevention of purulent complications of bone and soft-tissue structures when using external fixation pin-and-frame apparatus, device for postoperative wound sanitation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006010643A1 (en) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Using quaternary ammonium compounds to inhibit precipitation of fluoroquinolone antibiotics, particularly in ready-for-use formulations for veterinary medicine |
RU2349302C1 (en) * | 2007-09-21 | 2009-03-20 | Виталий Георгиевич Пшеничников | Pharmaceutical composition "oflomelid" for external application in pyoinflammatory disease treatment |
-
2016
- 2016-10-11 RU RU2016139700A patent/RU2682171C2/en active
Also Published As
Publication number | Publication date |
---|---|
RU2682171C2 (en) | 2019-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016139698A (en) | Pharmaceutical combination composition for local and external use on the basis of dioxidine | |
JP2021035984A (en) | Povidone iodine, novel alternative preservative for ophthalmic compositions | |
RU2016139699A (en) | Pharmaceutical combination composition for local and external use based on bacteriolytic and proteolytic complex of enzymes | |
KR20200084061A (en) | Ophthalmic compositions | |
RU2016139700A (en) | Pharmaceutical combination composition for the treatment of purulent wounds based on fluoroquinolones (options) | |
MX2020008360A (en) | Crystalline form of bictegravir sodium. | |
RU2011134713A (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING HCV POLYMERASE INHIBITOR PROCEDURE | |
JP2003128549A (en) | Composition applicable to mucous membrane | |
RU2017140078A (en) | COSMETIC METHOD AND ITS THERAPEUTIC APPLICATION TO REDUCE THE FATTY OF FAT TISSUE | |
RU2008147791A (en) | PHARMACEUTICAL COMPOSITION BASED ON CYCLOPHERON OF LOCAL AND EXTERNAL APPLICATION FOR TREATMENT OF PURULENT AND DESTRUCTIVE DISEASES OF Mucous and Skin, General Systemic Diseases in Immune Deficiency Conditions | |
RU2014141897A (en) | APPLICATION OF AMPHOTERIC SURFACE-ACTIVE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF PATHOGENIC VAGINAL VAGINAL BIOFILMS IN VAGINAL INFECTIONS | |
JP7330331B2 (en) | Aqueous ophthalmic composition and method for suppressing reduction in content of compound | |
RU2404773C2 (en) | Pharmaceutical composition based on acridonacetic acid and its compounds for treatment of suppurative-destructive lesions of mucous membrane and skin, general system diseases in case of immunodeficiency states | |
RU2010129409A (en) | METHOD FOR TREATING RABBIT PSOROPTOSIS AND CARNIVOR ANIMAL OTODEKTOSIS | |
MY198473A (en) | Glucono delta-lactone for treatment of vaginal fungal infections | |
RU2005104747A (en) | THE DRUG FOR THE TREATMENT OF POST-UNIVERSAL PURULAR-CATARAL ENDOMETRITIS AND MASTITIS IN COWS AND METHODS OF ITS APPLICATION | |
RU2012135798A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SKIN ITCH | |
RU2011136306A (en) | PHARMACEUTICAL ANTIBACTERIAL COMPOSITION FOR LOCAL USE ON THE BASIS OF ACTIVE BIOMETALLIC COMPLEXES | |
EA201400830A1 (en) | ANTIBACTERIAL PHARMACEUTICAL COMPOSITION | |
BR112021019054A2 (en) | Solid forms of an allosteric modifier compound of the HBV core protein | |
JP2017066033A (en) | Aqueous pharmaceutical composition | |
AU2014301961B2 (en) | Antimicrobial compositions and methods of use | |
RU2013110452A (en) | CYTOKIN-CONTAINING MEDICINES PREVENTING ANTIVIRAL, ANTI-MICROBIAL, IMMUNOMODULATING AND ANTI-INFLAMMATORY ACTION FOR PREVENTION AND TREATMENT OF INFECTIOUS DISEASES | |
RU2561049C1 (en) | Ophthalmic composition of eye drops for treating antibiotic-resistant infectious-inflammatory eye diseases | |
JP2012532130A (en) | Pharmaceutical ophthalmic solution composition containing a propionic acid derivative as a preservative |